Synapse - Works

Results (3351)

Mutational profiling of the oncogenome in non-small cell lung cancer (NSCLC)

Meeting Abstract

Pao, W.; McLellan, M. D.; Pham, D. K.; Singh, B.; Rusch, V. W.; Zakowski, M. F.; Miller, V. A.; Kris, M. G.; Wilson, R. K.; Varmus, H. E.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Genetic instability, response to DNA damage, and repair capacity in individuals with multiple primary non-small cell lung cancers

Meeting Abstract

Orlow, I.; Park, B.; Clas, B.; Mujumdar, U.; Dominguez, G.; Bhingradia, H.; Ginex, P.; Kris, M.; Rusch, V.; Begg, C.; more...
Lung Cancer (2005)

Fulltext@MSK | Save

Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC)

Meeting Abstract

Milton, D. T.; Kris, M. G.; Azzoli, C. G.; Gomez, J. E.; Heelan, R.; Krug, L. M.; Pao, W.; Pizzo, B.; Rizvi, N. A.; Miller, V. A.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

EGFR mutation, immumohistochemistry (IHC) and chromogenic in situ hybridization (CISH) as predictors of sensitivity to erlotinib and gefitinib in patients (pts) with NSCLC

Meeting Abstract

Miller, V. A.; Zakowski, M.; Riely, G. J.; Pao, W.; Hussain, S.; Ladanyi, M.; Heelan, R. T.; Kris, M. G.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Correlation of molecular markers including mutations with clinical outcomes in advanced non small cell lung cancer (NSCLC) patients (pts) treated with gefitinib, chemotherapy or chemotherapy and gefitinib in IDEAL and INTACT clinical trials

Meeting Abstract

Lynch, T. J.; Bell, D.; Haber, D.; Johnson, D.; Giaccone, G.; Fukuoka, M.; Kris, M.; Herbst, R.; Krebs, A.; Ochs, J.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Clinical testing for EGFR mutations in non-small cell lung cancer: Single laboratory experience with 253 consecutive cases

Meeting Abstract

Li, A. R.; Riely, G. J.; Zakowski, M. F.; Pao, W.; Pan, Q.; Ma, Y.; Miller, V. A.; Kris, M. G.; Ladanyi, M.
Journal of Molecular Diagnostics (2005)

Fulltext@MSK | Save

EGFR and KRAS mutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a phase II multicenter trial

Meeting Abstract

Kris, M. G.; Sandler, A.; Miller, V. A.; Zakowski, M. F.; Pao, W.; Tsao, A.; Patel, J. D.; Johnson, D. H.; Carbone, D. P.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Correlation of EGFR and KRAS mutation status, response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and survival with histologic subtypes of adenocarcinoma of the lung

Meeting Abstract

Hussain, S.; Zakowski, M. F.; Kris, M. G.; Ladanyi, M.; Pao, W.; Riely, G.; Rizvi, N.; Gomez, J. E.; Miller, V.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

The psychosocial world of women with advanced lung cancer

Meeting Abstract

Holland, J. C.; Gooen-Piels, J.; Zuckerman, E.; Culkin, A.; Kris, M.; Fleishman, S.; Kornblith, A. B.
Psycho-Oncology (2005)

Fulltext@MSK | Save

Phase 1 study of 10-propargyl-10-deazaaminopterin (PDX, pralatrexate) plus docetaxel in patients with advanced Non-Small Cell Lung Cancer (NSCLC)

Meeting Abstract

Gomez, J.; Azzoli, C.; Krug, L.; Ginsberg, M.; Henry, R.; Tyson, L.; Pizzo, B.; Dunne, M.; Kris, M.; Sirotnak, F.
Lung Cancer (2005)

Fulltext@MSK | Save